Last reviewed · How we verify
Nesacaine-Mpf (CHLOROPROCAINE)
Nesacaine-Mpf (generic name: CHLOROPROCAINE) is a Ester Local Anesthetic Small molecule drug developed by Fresenius Kabi. It is currently FDA-approved (first approved 1955) for Local anesthesia.
Nesacaine-Mpf is a small molecule medication used for pain control, particularly during cesarean delivery and other procedures such as spinal anesthesia. It is administered as a 2% injection solution, typically in the form of chloroprocaine hydrochloride.
At a glance
| Generic name | CHLOROPROCAINE |
|---|---|
| Sponsor | Fresenius Kabi |
| Drug class | Ester Local Anesthetic |
| Target | Sodium channel protein type 10 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1955 |
Approved indications
- Local anesthesia
Common side effects
- Seizures
- Coma
- Arrhythmias
- Death
- Cyanotic skin discoloration
- Abnormal coloration of the blood
- Methemoglobinemia
Key clinical trials
- The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population (PHASE2)
- Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population (PHASE3)
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections (PHASE4)
- Targeted Nerve Injection to the Knee (Nerve to Vastus Medialis): Comparing Two Adductor Canal Block Approaches (PHASE4)
- Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty (PHASE4)
- Flex Appeal: Evaluating the Efficacy of Anesthetic Techniques for Manipulation of Knees Under Anesthesia (PHASE4)
- The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine (PHASE4)
- Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nesacaine-Mpf CI brief — competitive landscape report
- Nesacaine-Mpf updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI
Frequently asked questions about Nesacaine-Mpf
What is Nesacaine-Mpf?
What is Nesacaine-Mpf used for?
Who makes Nesacaine-Mpf?
What is the generic name of Nesacaine-Mpf?
What drug class is Nesacaine-Mpf in?
When was Nesacaine-Mpf approved?
What development phase is Nesacaine-Mpf in?
What are the side effects of Nesacaine-Mpf?
What does Nesacaine-Mpf target?
Related
- Drug class: All Ester Local Anesthetic drugs
- Target: All drugs targeting Sodium channel protein type 10 subunit alpha
- Manufacturer: Fresenius Kabi — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Local anesthesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing